BioCentury
ARTICLE | Tools & Techniques

A headache for Synaptic

March 8, 1999 8:00 AM UTC

Efforts to develop safer members of a therapeutic class must carry the burden of their toxic forebears, a risk that may have snagged Eli Lilly and Co. in its effort to develop a selective serotonin receptor agonist identified as part of the pharma company's collaboration with Synaptic Pharmaceutical Corp.

Lilly was to have started this month a Phase III trial of LY334370 in migraine. But the company last week delayed the study following discussions with the FDA. The agent is the most advanced clinical compound in which Synaptic has any interest...